TRANSITION AND AMENDMENT AGREEMENTTransition and Amendment Agreement • December 13th, 2019 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Transition and Amendment Agreement (this “Agreement”) is made and entered into as of December 12, 2019 (the “Transition Date”) by and between Dr. Bhaskar Chaudhuri (the “Dr. Chaudhuri”) and Arcutis Biotherapeutics, Inc., a Delaware limited liability company (the “Company” and together with the Dr. Chaudhuri, the “Parties” and each, a “Party”).
OPTION NOTICE AND AMENDMENT NO. 2 TO EXCLUSIVE OPTION AND LICENSE AGREEMENTExclusive Option and License Agreement • December 13th, 2019 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations
THIS OPTION NOTICE AND AMENDMENT NO. 2 (this “Notice and Amendment”) to the Exclusive Option and License Agreement dated as of January 4, 2018 and amended on June 26, 2019 (the “Agreement”), by and between Arcutis Biotherapeutics, Inc., a United States corporation incorporated in the State of Delaware (“Arcutis”) and Jiangsu Hengrui Medicine Co., Ltd., a Chinese corporation (“Hengrui”) is entered into as of 5 December, 2019 (the “Effective Date”).
